{
    "clinical_study": {
        "@rank": "6521", 
        "arm_group": [
            {
                "arm_group_label": "Treatment Arm A - Maximum Therapeutic Dose", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of 33 mg/kg rounded to the nearest 250 mg of deferiprone tablets, deferiprone matching placebo tablets and one moxifloxacin matching placebo tablet."
            }, 
            {
                "arm_group_label": "Treatment Arm B - Supratherapeutic Dose", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of 50 mg/kg rounded to the nearest 250 mg of deferiprone tablets, and one moxifloxacin matching placebo tablet."
            }, 
            {
                "arm_group_label": "Treatment Arm C - Placebo Control", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of deferiprone matching placebo tablets and one moxifloxacin matching placebo tablet."
            }, 
            {
                "arm_group_label": "Treatment Arm D - Positive Control", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of deferiprone matching placebo tablets and one 400 mg moxifloxacin tablet."
            }
        ], 
        "brief_summary": {
            "textblock": "Single center, randomized, single-dose, double-blind, double-dummy, placebo and active\n      controlled, four-period crossover study to evaluate the effect of deferiprone on QTc\n      prolongation after administration of a single therapeutic (33 mg/kg) and supratherapeutic(50\n      mg/kg) oral doses of deferiprone in healthy volunteers as compared to placebo treatment."
        }, 
        "brief_title": "Through QT/QTc Trial to Evaluate the Potential of Deferiprone to Prolong the QT Interval in Healthy Subjects", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "detailed_description": {
            "textblock": "Post-marketing study to evaluate the effect of deferiprone and deferiprone 3-O-glucuronide\n      on QTc prolongation in healthy volunteers after administration of a single therapeutic (33\n      mg/kg) and supratherapeutic (50 mg/kg) oral dose of deferiprone and moxifloxacin (Avelox\u00ae)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Main Inclusion Criteria:\n\n          1. Healthy adult males or females, 18 - 45 years of age (inclusive).\n\n          2. Body weight \u2265 50 kg.\n\n          3. Body mass index (BMI) \u2265 19 and \u2264 32 kg/m2.\n\n          4. Medically healthy with clinically insignificant screening results (e.g., laboratory\n             profiles, medical history, vital signs, physical examination).\n\n          5. Absolute neutrophil count (ANC) of >1.5x109/L.\n\n          6. 12-lead ECGs which have no clinically significant findings as judged by the Principal\n             Investigator (PI) or the PI's designee at screening and check-in of each study\n             period,including:\n\n               1. Normal sinus rhythm (heart rate between 45 and 100 bpm);\n\n               2. QTcF interval \u2264 450 msec;\n\n               3. QRS interval \u2264 110 msec; and\n\n               4. PR interval \u2264 220 msec.\n\n          7. Subject must be capable of providing written informed consent, and must voluntarily\n             consent to participate in the study.\n\n          8. Willing to answer inclusion and exclusion criteria questionnaire at check-in.\n\n        Main Exclusion Criteria:\n\n          1. History or presence of significant respiratory, cardiovascular, pulmonary, hepatic,\n             renal, hematologic, gastrointestinal, endocrine, immunologic,\n             dermatologic,neurologic, or psychiatric disease.\n\n          2. Disorders or surgery of the gastrointestinal tract which may interfere with drug\n             absorption or may otherwise influence the PK of the investigational medicinal\n             products (e.g. cholecystectomy, resections of the small or large intestine, febrile\n             conditions, chronic diarrhea, chronic vomiting, endocrine disease, severe\n             infections,acute inflammations, etc.).\n\n          3. Presence of liver impairment: aspartate aminotransferase (AST), alanine\n             aminotransferase (ALT) above the normal reference range.\n\n          4. Presence of significant kidney impairment: serum creatinine higher than the normal\n             reference range.\n\n          5. Allergy to band aids, adhesive dressing or medical tape.\n\n          6. Clinically significant history or presence of ECG abnormalities such as second- or\n             third-degree atrioventricular block; evidence, or family history, of prolonged QT\n             syndrome.\n\n          7. Sustained sitting systolic blood pressure of <90 mmHg or >140 mmHg, or diastolic\n             blood pressure of >95 mmHg at screening or check-in of Period 1.\n\n          8. History or presence of hypersensitivity or idiosyncratic reaction to deferiprone,\n             moxifloxacin, iron chelators, or quinolone antibiotics.\n\n          9. History or presence of:\n\n               -  agranulocytosis;\n\n               -  asthma;\n\n               -  chronic bronchitis;\n\n               -  diabetes;\n\n               -  migraine;\n\n               -  hypertension;\n\n               -  hypotension;\n\n               -  hypokalemia;\n\n               -  seizures or epilepsy;\n\n               -  anaemia.\n\n         10. History or presence of alcoholism or drug abuse within the past 2 years.\n\n         11. Used tobacco/nicotine-containing product for at least 3 months prior to the first\n             dose of study.\n\n         12. Used Depo-Provera\u00ae or levonorgestrel implant within 90 days prior to the first dose\n             and throughout the study.\n\n         13. Participation in another clinical trial within 28 days prior to the first dose of the\n             study.\n\n         14. Had a clinically significant illness during the 4 weeks prior to check-in on Day -1\n             of Period 1."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01860703", 
            "org_study_id": "LA37-1111"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Treatment Arm A - Maximum Therapeutic Dose", 
                    "Treatment Arm B - Supratherapeutic Dose", 
                    "Treatment Arm D - Positive Control"
                ], 
                "intervention_name": "Deferiprone", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Ferriprox 500 mg tablets", 
                    "Deferiprone matching placebo tablets", 
                    "L1", 
                    "Moxifloxacin (Avelox\u00ae) 400 mg tablets", 
                    "Moxifloxacin matching placebo tablets"
                ]
            }, 
            {
                "arm_group_label": [
                    "Treatment Arm A - Maximum Therapeutic Dose", 
                    "Treatment Arm C - Placebo Control"
                ], 
                "intervention_name": "deferiprone matching placebo tablets", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment Arm A - Maximum Therapeutic Dose", 
                    "Treatment Arm B - Supratherapeutic Dose", 
                    "Treatment Arm C - Placebo Control"
                ], 
                "intervention_name": "moxifloxacin matching placebo tablet", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment Arm D - Positive Control", 
                "intervention_name": "moxifloxacin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Deferiprone", 
                "Moxifloxacin", 
                "Norgestimate, ethinyl estradiol drug combination"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Ferriprox\u00ae", 
            "LI", 
            "DFP", 
            "Deferiprone", 
            "Healthy Volunteers"
        ], 
        "lastchanged_date": "May 21, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tempe", 
                    "country": "United States", 
                    "state": "Arizona", 
                    "zip": "85283"
                }, 
                "name": "Celerion"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Double-Blind, Randomized, Crossover, Through QT/QTc Trial to Evaluate the Potential of Deferiprone to Prolong the QT Interval in Healthy Subjects", 
        "overall_official": {
            "affiliation": "ApoPharma", 
            "last_name": "Fernando Tricta, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The effects of deferiprone on QT interval will be measured using the following: the difference in change from baseline in Fridericia's QT corrected heart rate (dQTcF) between treatment and placebo (ddQTcF) at each postdose timepoint.", 
            "measure": "To evaluate the effects of deferiprone on QT interval (QT) and heart rate corrected QT interval (QTc) duration in healthy volunteers as compared to the effects of placebo treatment from baseline to 24 hours post-dose.", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline and at -0.75, -0.5, -0.25 pre-dose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2,3,4,6,8,10 and 24 hours post-dose."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01860703"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Safety will be assessed based on the number of adverse events (AEs) experienced.", 
                "measure": "To evaluate the number of adverse events in healthy subjects who received single therapeutic and supratherapeutic doses of deferiprone.", 
                "safety_issue": "Yes", 
                "time_frame": "Prior to dosing until 7 days +/- 1 day following dosing."
            }, 
            {
                "description": "Cmax will be evaluated from serum deferiprone and serum deferiprone 3-O-glucuronide concentration-time profiles.", 
                "measure": "To evaluate the maximum observed plasma concentration (Cmax) of deferiprone and deferiprone 3-O-glucuronide following administration of a single dose of 33 mg/kg deferiprone(the maximum recommended therapeutic dose).", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2,3,4,6,8,10 and 24 hours post-dose."
            }, 
            {
                "description": "The relationship between dQTcF and serum concentration profiles will be derived from parameter values collected from baseline to 24 hours post-dose, such as Cmax and AUC for deferiprone and deferiprone 3-O-glucuronide.", 
                "measure": "To assess the serum drug concentration-QT relationship (i.e., time course of QT and QTc interval prolongation in relation to serum levels of deferiprone and deferiprone 3-O-glucuronide).", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2,3,4,6,8,10 and 24 hours post-dose."
            }, 
            {
                "description": "The difference between deferiprone and placebo changes in QTC from baseline to 24 hours post-dose will be assessed using Bazett's correction (ddQTcB) at each post-dose timepoint, through calculation of HR, QT, QTc, PR, RR, and QRS for each assessment time point for each treatment and morphological changes of ECG waveform.", 
                "measure": "To evaluate the difference between deferiprone and placebo changes in QTc from baseline to 24 hours post-dose.", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2,3,4,6,8,10 and 24 hours post-dose."
            }, 
            {
                "description": "Cmax will be evaluated from serum deferiprone and serum deferiprone 3-O-glucuronide concentration-time profiles.", 
                "measure": "To evaluate the maximum observed plasma concentration (Cmax) of deferiprone and deferiprone 3-O-glucuronide following administration of a single dose of 50 mg/kg deferiprone (a supratherapeutic dose).", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2,3,4,6,8,10 and 24 hours post-dose."
            }, 
            {
                "description": "Tmax will be evaluated from serum deferiprone and serum deferiprone 3-O-glucuronide concentration-time profiles.", 
                "measure": "To evaluate the time to reach maximum observed plasma concentration (Tmax) of deferiprone and deferiprone 3-O-glucuronide following administration of a single dose of 33 mg/kg deferiprone(the maximum recommended therapeutic dose).", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2,3,4,6,8,10 and 24 hours post-dose."
            }, 
            {
                "description": "AUC will be evaluated from serum deferiprone and serum deferiprone 3-O-glucuronide concentration-time profiles.", 
                "measure": "To evaluate the area under the curve (AUC) of deferiprone and deferiprone 3-O-glucuronide following administration of a single dose of 33 mg/kg deferiprone(the maximum recommended therapeutic dose).", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2,3,4,6,8,10 and 24 hours post-dose."
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half from serum deferiprone and serum deferiprone 3-O-glucuronide samples.", 
                "measure": "To evaluate the plasma decay half- life (t1/2)  of deferiprone and deferiprone 3-O-glucuronide following administration of a single dose of 33 mg/kg deferiprone(the maximum recommended therapeutic dose).", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2,3,4,6,8,10 and 24 hours post-dose."
            }, 
            {
                "description": "Tmax will be evaluated from serum deferiprone and serum deferiprone 3-O-glucuronide concentration-time profiles.", 
                "measure": "To evaluate the time to reach maximum observed plasma concentration (Tmax) of deferiprone and deferiprone 3-O-glucuronide following administration of a single dose of 50 mg/kg deferiprone (a supratherapeutic dose).", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2,3,4,6,8,10 and 24 hours post-dose."
            }, 
            {
                "description": "AUC will be evaluated from serum deferiprone and serum deferiprone 3-O-glucuronide concentration-time profiles.", 
                "measure": "To evaluate the area under the curve (AUC) of deferiprone and deferiprone 3-O-glucuronide following administration of a single dose of 50 mg/kg deferiprone (a supratherapeutic dose).", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2,3,4,6,8,10 and 24 hours post-dose."
            }, 
            {
                "description": "Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half from serum deferiprone and serum deferiprone 3-O-glucuronide samples.", 
                "measure": "To evaluate the plasma decay half-life (t1/2) of deferiprone and deferiprone 3-O-glucuronide following administration of a single dose of 50 mg/kg deferiprone (a supratherapeutic dose).", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2,3,4,6,8,10 and 24 hours post-dose."
            }, 
            {
                "description": "Safety will be assessed based on any changes in standard 12-lead ECG results.", 
                "measure": "To evaluate any changed in standard 12-lead ECG results in healthy subjects who received single therapeutic and supratherapeutic doses of deferiprone.", 
                "safety_issue": "Yes", 
                "time_frame": "Prior to dosing until 7 days +/- 1 day following dosing."
            }
        ], 
        "source": "ApoPharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ApoPharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}